In this phase 2b randomized controlled trial, treatment with FGF21 analogue pegozafermin, a novel therapy for treating NASH, led to improvements in liver fat and fibro-inflammation (liver disease activity) quantified by cT1 from baseline up to 24 weeks. These results support the advancement of pegozafermin into phase 3 development.
Welcome to Perspectum Medical Education
You are entering a website that is scientific in nature and created for healthcare professionals.
Are you a healthcare professional?